AnaptysBio Inc (ANAB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 30/100 (MEDIUM), 30.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 26.79% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
- AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
- AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
- AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
- AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
- Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
- Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)
- Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial. — Nat Med 2026 Sep PMID 42722888
- Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1. — J Am Acad Dermatol 2026 Sep 1 PMID 42680109
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
- Alopecia Areata: Current and Emerging Therapies. — Drugs 2026 Aug 19 PMID 42616344
- Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries. — Paediatr Drugs 2026 Aug 13 PMID 42595931
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AnaptysBio Inc.
Full ANAB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.